Opinion|Videos|November 25, 2024

Current Landscape of Bispecific Therapies for RRMM

Key Takeaways

  • Bispecific therapies target both tumor antigens and T-cell receptors, enhancing immune responses against myeloma cells in RRMM.
  • Several bispecific antibodies are approved or in clinical trials, showing promise in overcoming resistance to conventional therapies.
SHOW MORE

Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple

Video content above is prompted by the following

  • Provide a brief overview of the bispecific therapies currently available for the treatment of relapsed/refractory multiple myeloma (RRMM).

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME